These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1229 related articles for article (PubMed ID: 11686352)
1. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352 [TBL] [Abstract][Full Text] [Related]
2. Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Smith MP; Ludlam CA; Collins PW; Hay CR; Wilde JT; Grigeri A; Melsen T; Savidge GF Thromb Haemost; 2001 Oct; 86(4):949-53. PubMed ID: 11686351 [TBL] [Abstract][Full Text] [Related]
3. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160 [TBL] [Abstract][Full Text] [Related]
5. Continuous infusion of recombinant factor VIIa for surgery in patients with deficiency of factor VII. Schulman S; Tjønnfjord GE; Wallensten R; Martinowitz U; Kenet G Thromb Haemost; 2005 Dec; 94(6):1177-80. PubMed ID: 16411390 [TBL] [Abstract][Full Text] [Related]
6. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Shapiro AD; Gilchrist GS; Hoots WK; Cooper HA; Gastineau DA Thromb Haemost; 1998 Nov; 80(5):773-8. PubMed ID: 9843170 [TBL] [Abstract][Full Text] [Related]
7. Feasibility of using recombinant factor VIIa in continuous infusion. Schulman S; Bech Jensen M; Varon D; Keller N; Gitel S; Horoszowski H; Heim M; Martinowitz U Thromb Haemost; 1996 Mar; 75(3):432-6. PubMed ID: 8701403 [TBL] [Abstract][Full Text] [Related]
8. Recombinant activated factor VIIa in uncontrolled bleeding: a haemostasis laboratory study in non-haemophilia patients. Brandsborg S; Sørensen B; Poulsen LH; Ingerslev J Blood Coagul Fibrinolysis; 2006 Jun; 17(4):241-9. PubMed ID: 16651865 [TBL] [Abstract][Full Text] [Related]
9. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela. Boadas A; Fernández-Palazzi F; De Bosch NB; Cedeño M; Ruiz-Sáez A Haemophilia; 2011 May; 17(3):422-7. PubMed ID: 21118333 [TBL] [Abstract][Full Text] [Related]
10. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Giangrande PL; Wilde JT; Madan B; Ludlam CA; Tuddenham EG; Goddard NJ; Dolan G; Ingerslev J Haemophilia; 2009 Mar; 15(2):501-8. PubMed ID: 19187194 [TBL] [Abstract][Full Text] [Related]
11. [Continuous infusion of recombinant activated factor VII during and after elbow arthroplasty in a hemophilia A patient with inhibitors]. Nakamura M; Terashima K; Takashima Y; Amano K; Horikoshi Y; Mimaya J Rinsho Ketsueki; 2002 Mar; 43(3):183-8. PubMed ID: 11979750 [TBL] [Abstract][Full Text] [Related]
12. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Scharrer I Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179 [TBL] [Abstract][Full Text] [Related]
13. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Ludlam CA; Smith MP; Morfini M; Gringeri A; Santagostino E; Savidge GF Br J Haematol; 2003 Mar; 120(5):808-13. PubMed ID: 12614214 [TBL] [Abstract][Full Text] [Related]
15. Single higher dose of recombinant activated factor VII in the treatment of hemorrhages in patients with hemophilia complicated by inhibitors. Łaguna P; Mital A Adv Clin Exp Med; 2012; 21(4):519-24. PubMed ID: 23240458 [TBL] [Abstract][Full Text] [Related]
16. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency. Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044 [TBL] [Abstract][Full Text] [Related]
17. Intraoperative use of recombinant activated factor VII (rFVIIa). De Gasperi A Minerva Anestesiol; 2006 Jun; 72(6):489-94. PubMed ID: 16682921 [TBL] [Abstract][Full Text] [Related]
18. Clinical experience with activated factor VII: focus on safety aspects. Roberts HR Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S115-8. PubMed ID: 9819041 [TBL] [Abstract][Full Text] [Related]
19. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia. Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381 [TBL] [Abstract][Full Text] [Related]
20. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder. Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]